Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Posted: 23 July 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that positive feedback has been received from the US…
Rapid drug test to provide patients with better care
Posted: 23 July 2024 Teams at two of Melbourne’s leading research and medical institutes are developing high-tech solutions to rapidly test for drugs and better treat patients presenting to hospital. The researchers from the Colonial Foundation Healthy Ageing Centre –…
Breakthrough in high-performance computing and quantum chemistry revolutionises drug discovery
Posted: 23 July 2024 A breakthrough in high-performance computing (HPC) and quantum chemistry, powered by the world’s fastest supercomputer and leading technology, is set to revolutionise drug discovery and unlock new ways to target a range of diseases.…
Why early life antibiotic use can increase risk of asthma: a potential prevention for asthma later in life?
Posted: 23 July 2024 Early exposure to antibiotics can trigger long term susceptibility to asthma, according to new research from Monash University. Importantly the research team isolated a molecule produced by gut bacteria that in the future could…
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
Posted: 23 July 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and…
Melbourne merger for a united vision and stronger Victoria
Posted: 16 July 2024 We are delighted to announce that Committee for Melbourne and Melbourne Chamber of Commerce intend to come together to create a stronger voice to advocate for the future of Greater Melbourne. The expanded Committee…
Optiscan Receives Ethical Clearance for Breast Cancer Study
Posted: 16 July 2024 Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to announce that it has received ethical clearance from the Royal Melbourne Hospital Human Research Ethics Committee to undertake an in vivo clinical study…
Hub opens opportunities for new disease treatments
Posted: 16 July 2024 A new treatment that could potentially reverse or stop progression of traumatic brain injury will be developed at a new state-of-the-art biotechnology facility launched at La Trobe University. The $8 million Bio Innovation Hub,…
Florey biotech spin-out secures seed investment from Curie.Bio
Posted: 16 July 2024 Alkira Bio uses its proprietary LASEREDD® technology platform to discover therapeutic antibodies directed against previously out of reach targets, pioneering new possibilities for drug discovery. The seed financing from Curie.Bio recognises Alkira Bio’s advanced…
Cumming Global Centre for Pandemic Therapeutics awards AU$5 million in grant funding
Posted: 16 July 2024 Monash University researchers will develop a first of its kind inhaler device to conveniently treat respiratory viruses, while University of York researchers will screen 200 animal viruses to assess human pandemic risk and inform proactive…
Backing The Next Generation Of Life-Saving Treatments And Jobs
Posted: 16 July 2024 The Allan Labor Government is ensuring Victoria’s medical research sector can continue to drive nation-leading infectious disease treatments and develop new products, grow exports and create jobs – with the opening of the Medicines Manufacturing…
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Posted: 16 July 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase…
